Search research articles
Contact Us
Filters
Showing results (31-40 of 79) with videos related to
Page
of 8
Sort By:
International Journal of Molecular Sciences
|
October 27, 2022
Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with <i>CFTR</i> Mutations Causing Pancreatic Insufficiency
Harold Tabori, Jochen Schneider, Stefan Lüth, et al.
Journal of Bone and Mineral Metabolism
|
September 2, 2008
Cross-sectional study on bone density-related sonographic parameters in children with asthma: correlation to therapy with inhaled corticosteroids and disease severity
Jochen G Mainz, Dieter Sauner, Ansgar Malich, et al.
Expert Opinion on Drug Delivery
|
February 3, 2015
Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand?
Mareike Klinger-Strobel, Christian Lautenschläger, Dagmar Fischer, et al.
Frontiers in Immunology
|
May 24, 2021
Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid
Jochen G Mainz, Christin Arnold, Kara Wittstock, et al.
The Journal of Pediatrics
|
November 26, 2019
Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis
Ellison Suthoff, Jochen G Mainz, Desmond W Cox, et al.
Journal of Fungi (Basel, Switzerland)
|
September 26, 2025
Impact of Antibiotic Therapy on the Upper Respiratory Tract and Gut Mycobiome in Patients with Cystic Fibrosis
Cristina Zubiria-Barrera, Malena Bos, Robert Neubert, et al.
Auris, Nasus, Larynx
|
October 30, 2010
Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial
Jochen G Mainz, Isabella Schiller, Christiane Ritschel, et al.
BMC Pulmonary Medicine
|
August 15, 2019
Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study
Scott C Bell, Jochen G Mainz, Gordon MacGregor, et al.
Klinische Padiatrie
|
May 6, 2025
Improvement of abdominal symptoms in people with Cystic Fibrosis during therapy with Elexacaftor/Tezacaftor/Ivacaftor brings gastrointestinal involvement into the paediatric pulmonologist's focus
Pauline Sadrieh, Lutz Nährlich, Carsten Schwarz, et al.
Frontiers in Immunology
|
December 5, 2022
Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage
Nina Erdmann, Theresa Schilling, Julia Hentschel, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 79) with videos related to
Sort By:
Page
of 8
International Journal of Molecular Sciences
|
October 27, 2022
Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with <i>CFTR</i> Mutations Causing Pancreatic Insufficiency
Harold Tabori, Jochen Schneider, Stefan Lüth, et al.
Journal of Bone and Mineral Metabolism
|
September 2, 2008
Cross-sectional study on bone density-related sonographic parameters in children with asthma: correlation to therapy with inhaled corticosteroids and disease severity
Jochen G Mainz, Dieter Sauner, Ansgar Malich, et al.
Expert Opinion on Drug Delivery
|
February 3, 2015
Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand?
Mareike Klinger-Strobel, Christian Lautenschläger, Dagmar Fischer, et al.
Frontiers in Immunology
|
May 24, 2021
Ivacaftor Reduces Inflammatory Mediators in Upper Airway Lining Fluid From Cystic Fibrosis Patients With a G551D Mutation: Serial Non-Invasive Home-Based Collection of Upper Airway Lining Fluid
Jochen G Mainz, Christin Arnold, Kara Wittstock, et al.
The Journal of Pediatrics
|
November 26, 2019
Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis
Ellison Suthoff, Jochen G Mainz, Desmond W Cox, et al.
Journal of Fungi (Basel, Switzerland)
|
September 26, 2025
Impact of Antibiotic Therapy on the Upper Respiratory Tract and Gut Mycobiome in Patients with Cystic Fibrosis
Cristina Zubiria-Barrera, Malena Bos, Robert Neubert, et al.
Auris, Nasus, Larynx
|
October 30, 2010
Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial
Jochen G Mainz, Isabella Schiller, Christiane Ritschel, et al.
BMC Pulmonary Medicine
|
August 15, 2019
Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study
Scott C Bell, Jochen G Mainz, Gordon MacGregor, et al.
Klinische Padiatrie
|
May 6, 2025
Improvement of abdominal symptoms in people with Cystic Fibrosis during therapy with Elexacaftor/Tezacaftor/Ivacaftor brings gastrointestinal involvement into the paediatric pulmonologist's focus
Pauline Sadrieh, Lutz Nährlich, Carsten Schwarz, et al.
Frontiers in Immunology
|
December 5, 2022
Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage
Nina Erdmann, Theresa Schilling, Julia Hentschel, et al.
Page
of 8